SEARCH

SEARCH BY CITATION

References

  • 1
    Brawley O, Byers T, Chen A, et al. New American Cancer Society process for creating trustworthy cancer screening guidelines. JAMA. 2011; 306: 2495-2499.
  • 2
    Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2012: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2012; 62: 129-142.
  • 3
    Smith RA, Saslow D, Sawyer KA, et al; American Cancer Society High-Risk Work Group; American Cancer Society Screening Older Women Work Group; American Cancer Society Mammography Work Group; American Cancer Society Physical Examination Work Group; American Cancer Society New Technologies Work Group; American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin. 2003; 53: 141-169.
  • 4
    Saslow D, Boetes C, Burke W, et al; American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007; 57: 75-89.
  • 5
    Saslow D, Runowicz CD, Solomon D, et al; American Cancer Society. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002; 52: 342-362.
  • 6
    Saslow D, Castle PE, Cox JT, et al; Gynecologic Cancer Advisory Group, Garcia F. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007; 57: 7-28.
  • 7
    Saslow D, Solomon D, Lawson HW, et al; ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012; 62: 147-172.
  • 8
    Smith RA, von Eschenbach AC, Wender R, et al; ACS Prostate Cancer Advisory Committee, ACS Colorectal Cancer Advisory Committee, ACS Endometrial Cancer Advisory Committee. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001-testing for early lung cancer detection. CA Cancer J Clin. 2001; 51: 38-75; quiz 77-80.
  • 9
    Levin B, Brooks D, Smith RA, Stone A. Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers. CA Cancer J Clin. 2003; 53: 44-55.
  • 10
    Rex DK, Kahi CJ, Levin B, et al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and US Multi-Society Task Force on Colorectal Cancer. CA Cancer J Clin. 2006; 56: 160-167; quiz 185-186.
  • 11
    Winawer SJ, Zauber AG, Fletcher RH, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. CA Cancer J Clin. 2006; 56: 143-159; quiz 184-185.
  • 12
    Levin B, Lieberman DA, McFarland B, et al; American Cancer Society Colorectal Cancer Advisory Group; US Multi-Society Task Force; American College of Radiology Colon Cancer Committee. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008; 58: 130-160.
  • 13
    Wolf AM, Wender RC, Etzioni RB, et al; American Cancer Society Prostate Cancer Advisory Committee. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010; 60: 70-98.
  • 14
    American Cancer Society Lung Cancer Guidance Workgroup. Interim Guidance on Lung Cancer Screening. cancer.org/Healthy/FindCancerEarly/index. Accessed December 1, 2011.
  • 15
    Wender R, Fontham ETH, Barrera E Jr, et al. American Cancer Society lung cancer screening guidelines [published online ahead of print January 11, 2013]. CA Cancer J Clin.
  • 16
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
  • 17
    Tabar L, Duffy SW, Vitak B, Chen HH, Prevost TC. The natural history of breast carcinoma: what have we learned from screening? Cancer. 1999; 86: 449-462.
  • 18
    Duffy SW, Tabar L, Olsen AH, et al. Absolute numbers of lives saved and overdiagnosis in breast cancer screening, from a randomized trial and from the Breast Screening Programme in England. J Med Screen. 2010; 17: 25-30.
  • 19
    Tabar L, Vitak B, Chen TH, et al. Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology. 2011; 260: 658-663.
  • 20
    EUROSCREEN Working Group. Summary of the evidence of breast cancer service screening outcomes in Europe and first estimate of the benefit and harm balance sheet. J Med Screen. 2012; 19( suppl 1): 5-13.
  • 21
    Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012; 367: 1998-2005.
  • 22
    Puliti D, Zappa M, Miccinesi G, Falini P, Crocetti E, Paci E. An estimate of overdiagnosis 15 years after the start of mammographic screening in Florence. Eur J Cancer. 2009; 45: 3166-3171.
  • 23
    Yen MF, Tabar L, Vitak B, Smith RA, Chen HH, Duffy SW. Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. Eur J Cancer. 2003; 39: 1746-1754.
  • 24
    Puliti D, Duffy SW, Miccinesi G, et al. Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J Med Screen. 2012; 19( suppl 1): 42-56.
  • 25
    Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA. 2001; 285: 2750-2756.
  • 26
    Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer. 1994; 73: 643-651.
  • 27
    Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004; 23: 1111-1130.
  • 28
    Berry DA, Iversen ES Jr, Gudbjartsson DF, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002; 20: 2701-2712.
  • 29
    Antoniou AC, Pharoah PP, Smith P, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer. 2004; 91: 1580-1590.
  • 30
    Jacobi CE, de Bock GH, Siegerink B, van Asperen CJ. Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose? Breast Cancer Res Treat. 2009; 115: 381-390.
  • 31
    Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989; 81: 1879-1886.
  • 32
    Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012; 380: 1778-1786.
  • 33
    Giordano L, von Karsa L, Tomatis M, et al. Mammographic screening programmes in Europe: organization, coverage and participation. J Med Screen. 2012; 19( suppl 1): 72-82.
  • 34
    Hofvind S, Ponti A, Patnick J, et al. False-positive results in mammographic screening for breast cancer in Europe: a literature review and survey of service screening programmes. J Med Screen. 2012; 19( suppl 1): 57-66.
  • 35
    Njor S, Nystrom L, Moss S, et al; Euroscreen Working Group. Breast cancer mortality in mammographic screening in Europe: a review of incidence-based mortality studies. J Med Screen. 2012; 19( suppl 1): 33-41.
  • 36
    Moss SM, Nystrom L, Jonsson H, et al; Euroscreen Working Group. The impact of mammographic screening on breast cancer mortality in Europe: a review of trend studies. J Med Screen. 2012; 19( suppl 1): 26-32.
  • 37
    Giordano L, Cogo C, Patnick J, Paci E; Euroscreen Working Group. Communicating the balance sheet in breast cancer screening. J Med Screen. 2012; 19( suppl 1): 67-71.
  • 38
    Broeders M, Moss S, Nystrom L, et al; EUROSCREEN Working Group. The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. J Med Screen. 2012; 19( suppl 1): 14-25.
  • 39
    Howlander N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2009. Bethesda, MD: National Cancer Institute; 2012.
  • 40
    Moyer VA; U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 156: 880-891, W312.
  • 41
    Centers for Disease Control and Prevention (CDC). USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. MMWR Morb Mortal Wkly Rep. 1995; 44( RR-8): 1-34.
  • 42
    Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H; National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009; 58( RR-4): 1-207; quiz CE1-4.
  • 43
    Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among adolescents aged 13-17 years-United States, 2011. MMWR Morb Mortal Wkly Rep. 2012; 61: 671-677.
  • 44
    Collins JF, Lieberman DA, Durbin TE, Weiss DG; Veterans Affairs Cooperative Study #380 Group. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med. 2005; 142: 81-85.
  • 45
    Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2008; 149: 659-669.
  • 46
    Winawer S, Fletcher R, Rex D, et al; Gastrointestinal Consortium Panel. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology. 2003; 124: 544-560.
  • 47
    Rex DK, Kahi CJ, Levin B, et al; American Cancer Society; US Multi-Society Task Force on Colorectal Cancer. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2006; 130: 1865-1871.
  • 48
    Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR; United States Multi-Society Task Force on Colorectal Cancer. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012; 143: 844-857.
  • 49
    Schoen RE, Pinsky PF, Weissfeld JL, et al; PLCO Project Team. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med. 2012; 366: 2345-2357.
  • 50
    Atkin WS, Edwards R, Kralj-Hans I, et al; UK Flexible Sigmoidoscopy Trial Investigators. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010; 375: 1624-1633.
  • 51
    Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med. 1993; 329: 1977-1981.
  • 52
    Zauber AG, Winawer SJ, O'Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012; 366: 687-696.
  • 53
    Allison JE. FIT: a valuable but underutilized screening test for colorectal cancer-it's time for a change. Am J Gastroenterol. 2010; 105: 2026-2028.
  • 54
    Bretthauer M, Kalager M. Colonoscopy as a triage screening test. N Engl J Med. 2012; 366: 759-760.
  • 55
    Telford JJ, Levy AR, Sambrook JC, Zou D, Enns RA. The cost-effectiveness of screening for colorectal cancer. CMAJ. 2010; 182: 1307-1313.
  • 56
    Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2008; 149: 659-669.
  • 57
    Bandi P, Cokkinides V, Smith RA, Jemal A. Trends in colorectal cancer screening with home-based fecal occult blood tests in adults ages 50 to 64 years, 2000-2008. Cancer. 2012; 118: 5092-5099.
  • 58
    Levin TR, Jamieson L, Burley DA, Reyes J, Oehrli M, Caldwell C. Organized colorectal cancer screening in integrated health care systems. Epidemiol Rev. 2011; 33: 101-110.
  • 59
    Byers T. Examining stools for colon cancer prevention: what are we really looking for? Cancer Prev Res (Phila). 2011; 4: 1531-1533.
  • 60
    Zapka JM, Klabunde CN, Arora NK, Yuan G, Smith JL, Kobrin SC. Physicians' colorectal cancer screening discussion and recommendation patterns. Cancer Epidemiol Biomarkers Prev. 2011; 20: 509-521.
  • 61
    von Eschenbach A, Ho R, Murphy GP, Cunningham M, Lins N. American Cancer Society guidelines for the early detection of prostate cancer: update, June 10, 1997. Cancer. 1997; 80: 1805-1807.
  • 62
    Lim LS, Sherin K; ACPM Prevention Practice Committee. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice. Am J Prev Med. 2008; 34: 164-170.
  • 63
    American Urological Association. Prostate-Specific Antigen Best Practice Statement: 2009 Update. auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/psa09.pdf. Accessed October 4, 2010.
  • 64
    Chan EC, Vernon SW, O'Donnell FT, Ahn C, Greisinger A, Aga DW. Informed consent for cancer screening with prostate-specific antigen: how well are men getting the message? Am J Public Health. 2003; 93: 779-785.
  • 65
    Hoffman RM, Couper MP, Zikmund-Fisher BJ, et al. Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study). Arch Intern Med. 2009; 169: 1611-1618.
  • 66
    Davis K, Haisfield L, Dorfman C, Krist A, Taylor KL. Physicians' attitudes about shared decision making for prostate cancer screening. Fam Med. 2011; 43: 260-266.
  • 67
    Schroder FH, Hugosson J, Roobol MJ, et al; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360: 1320-1328.
  • 68
    Andriole GL, Crawford ED, Grubb RL 3rd, et al; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360: 1310-1319.
  • 69
    U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008; 149: 185-191.
  • 70
    Moyer VA; U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 157: 120-134.
  • 71
    Carlsson S, Vickers AJ, Roobol M, et al. Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. J Clin Oncol. 2012; 30: 2581-2584.
  • 72
    Brawley OW. Prostate cancer screening: what we know, don't know, and believe. Ann Intern Med. 2012; 157: 135-136.
  • 73
    Wilt TJ, Brawer MK, Jones KM, et al; Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012; 367: 203-213.
  • 74
    Walker JL, Nunez ER. Endometrial cancer. In: Kramer BS, Gohagan JK, Prorok PC, eds. Cancer Screening: Theory and Practice. New York City: Marcel Dekker, Inc; 1999: 531-566.
  • 75
    Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet. 1999; 354: 99-105.
  • 76
    National Cancer Institute. Statement Concerning the Lung Cancer Screening Trial. cancer.gov/images/DSMB-NLST.pdf. Accessed October 28, 2010.
  • 77
    National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365: 395-409.
  • 78
    Fontham ETH, Wender R, Barrera E, et al. American Cancer Society Interim Guidance on Lung Cancer Screening. cancer.org/acs/groups/content/@editorial/documents/document/acspc-030879.pdf. Accessed October 1, 2012.
  • 79
    Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012; 307: 2418-2429.
  • 80
    Johnson CC, Kessel B, Riley TL, et al; Prostate, Lung Colorectal and Ovarian Cancer Project Team. The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. Gynecol Oncol. 2008; 110: 383-389.
  • 81
    Duffy MJ, Bonfrer JM, Kulpa J, et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer. 2005; 15: 679-691.
  • 82
    Moss EL, Hollingworth J, Reynolds TM. The role of CA125 in clinical practice. J Clin Pathol. 2005; 58: 308-312.
  • 83
    Fishman DA, Cohen L, Blank SV, et al. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol. 2005; 192: 1214-1221; discussion 1221-1222.
  • 84
    Ren J, Cai H, Li Y, et al. Tumor markers for early detection of ovarian cancer. Expert Rev Mol Diagn. 2010; 10: 787-798.
  • 85
    Kobayashi E, Ueda Y, Matsuzaki S, et al. Biomarkers for screening, diagnosis, and monitoring of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2012; 21: 1902-1912.
  • 86
    Prorok PC, Andriole GL, Bresalier RS, et al; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000; 21( suppl 6): 273S-309S.
  • 87
    Buys SS, Partridge E, Black A, et al; PLCO Project Team. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011; 305: 2295-2303.
  • 88
    Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009; 10: 327-340.
  • 89
    Pinsky PF, Zhu C, Skates SJ, et al. Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial [published online ahead of print October 15, 2012]. Int J Cancer.
  • 90
    U.S. Preventive Services Task Force. Screening for Ovarian Cancer: U.S. Preventive Services Task Force Reaffirmation Recommendation Statement [published online ahead of print September 11, 2012]. Ann Intern Med.
  • 91
    National Institutes of Health. National Institutes of Health Consensus Development Conference Statement. Ovarian Cancer: Screening Treatment, and Followup. NIH Consensus Statement 1994. Bethesda, MD: National Institutes of Health; 1994: 1-30.
  • 92
    Eddy D. ACS report on the cancer-related health checkup. CA Cancer J Clin. 1980; 30: 193-240.
  • 93
    Maciosek MV, Coffield AB, Edwards NM, Flottemesch TJ, Goodman MJ, Solberg LI. Priorities among effective clinical preventive services: results of a systematic review and analysis. Am J Prev Med. 2006; 31: 52-61.
  • 94
    Fenton JJ, Cai Y, Weiss NS, et al. Delivery of cancer screening: how important is the preventive health examination? Arch Intern Med. 2007; 167: 580-585.
  • 95
    Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2008: a review of current American Cancer Society guidelines and cancer screening issues. CA Cancer J Clin. 2008; 58: 161-179.
  • 96
    Miles A, Cockburn J, Smith RA, Wardle J. A perspective from countries using organized screening programs. Cancer. 2004; 101 ( suppl 5): 1201-1213.
  • 97
    Anhang Price R, Zapka J, Edwards H, Taplin SH. Organizational factors and the cancer screening process. J Natl Cancer Inst Monogr. 2010; 2010: 38-57.
  • 98
    Davis K, Abrams M, Stremikis K. How the Affordable Care Act will strengthen the nation's primary care foundation. J Gen Intern Med. 2011; 26: 1201-1203.
  • 99
    Ferrante JM, Balasubramanian BA, Hudson SV, Crabtree BF. Principles of the patient-centered medical home and preventive services delivery. Ann Fam Med. 2010; 8: 108-116.
  • 100
    Meissner HI, Klabunde CN, Han PK, Benard VB, Breen N. Breast cancer screening beliefs, recommendations and practices: primary care physicians in the United States. Cancer. 2011; 117: 3101-3111.
  • 101
    Meissner HI, Tiro JA, Yabroff KR, Haggstrom DA, Coughlin SS. Too much of a good thing?Physician practices and patient willingness for less frequent pap test screening intervals. Med Care. 2010; 48: 249-259.
  • 102
    Beydoun HA, Beydoun MA. Predictors of colorectal cancer screening behaviors among average-risk older adults in the United States. Cancer Causes Control. 2008; 19: 339-359.
  • 103
    Sohl SJ, Moyer A. Tailored interventions to promote mammography screening: a meta-analytic review. Prev Med. 2007; 45: 252-261.
  • 104
    Sarfaty M, Myers RE, Harris DM, et al. Variation in colorectal cancer screening steps in primary care: basis for practice improvement. Am J Med Qual. 2012; 27: 458-466.
  • 105
    Sifri R, Wender R, Lieberman D, et al. Developing a quality screening colonoscopy referral system in primary care practice: a report from the National Colorectal Cancer Roundtable. CA Cancer J Clin. 2010; 60: 40-49.
  • 106
    Nocon RS, Sharma R, Birnberg JM, Ngo-Metzger Q, Lee SM, Chin MH. Association between patient-centered medical home rating and operating cost at federally funded health centers. JAMA. 2012; 308: 60-66.
  • 107
    Patel UB, Rathjen C, Rubin E. Horizon's patient-centered medical home program shows practices need much more than payment changes to transform. Health Aff (Millwood). 2012; 31: 2018-2027.
  • 108
    Sarfaty M, Wender R, Smith R. Promoting cancer screening within the patient centered medical home. CA Cancer J Clin. 2011; 61: 397-408.
  • 109
    Trivedi AN, Rakowski W, Ayanian JZ. Effect of cost sharing on screening mammography in Medicare health plans. N Engl J Med. 2008; 358: 375-383.
  • 110
    Henry J. Kaiser Family Foundation, American Cancer Society, National Colorectal Cancer Roundtable. Coverage of Colonoscopies Under the Affordable Care Act's Prevention Benefits. Menlo Park, CA: Henry J. Kaiser Family Foundation, American Cancer Society, National Colorectal Cancer Foundation; 2012. Available at: kff.org/healthreform/upload/8351.pdf. Accessed December 1, 2012.
  • 111
    Smith RA, Cokkinides V, Brooks D, Saslow D, Brawley OW. Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2010; 60: 99-119.
  • 112
    Ward E, Halpern M, Schrag N, et al. Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin. 2008; 58: 9-31.
  • 113
    Levy AR, Bruen BK, Ku L. Health care reform and women's insurance coverage for breast and cervical cancer screening. Prev Chronic Dis. 2012; 9: E159.
  • 114
    Baicker K, Finkelstein A. The effects of Medicaid coverage-learning from the Oregon experiment. N Engl J Med. 2011; 365: 683-685.